SS
CTMX icon

SBI Securities’s CytomX Therapeutics CTMX Stock Holding History

SBI Securities’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105 Hold
28
– – ﹤0.01% 3498
2026
Q1 		$132 Hold
28
– – ﹤0.01% 3344
2025
Q4 		$119 Sell
28
-57
-67% -$217 ﹤0.01% 3358
2025
Q3 		$271 Buy
85
+1
+1% +$2 ﹤0.01% 3217
2025
Q2 		$191 Sell
84
-24
-22% -$39 ﹤0.01% 3326
2025
Q1 		$69 Sell
108
-999
-90% -$775 ﹤0.01% 3560
2024
Q4 		$1.14K Buy
+1,107
New +$1.19K ﹤0.01% 2547

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SBI Securities's CTMX Position: Q2 2026 in Review

SBI Securities held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 28 shares worth $105. The position accounts for ﹤0.01% of the portfolio, ranked #3498.

SBI Securities first reported a position in CTMX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.14K in Q4 2024. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • SBI Securities held 28 shares of CytomX Therapeutics worth $105 as of Q2 2026.
  • SBI Securities left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3498 holding.
  • SBI Securities first reported a position in CytomX Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's CytomX Therapeutics position peaked at $1.14K in Q4 2024.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.